The Cystic Fibrosis
Foundation Mutation
Analysis Program (MAP)
What is the
Mutation Analysis Program (MAP)?
Program Information
The MAP is a valuable program that provides free genotyping and follow-up testing as needed for people with cystic fibrosis. The MAP is only available to patients with cystic fibrosis. Utilization of the program will help CF patients identify which CFTR mutation they have. Once the patient’s mutation is identified, the patient and provider can make informed decisions about the appropriate treatment options.
The MAP is a
valuable program
that provides free
genotyping and
follow-up testing
as needed for
people with
cystic fibrosis.
Step-by-Step Process for Providers
Follow the simple step-by-step process to enroll your patient in the Mutation Analysis Program:
Call 888-315-4154 for screening and to obtain the enrollment form
Complete the enrollment form
Fax or mail in the completed form
Once approved, an authorization number will be assigned
The enrollment form and authorization number will be sent back to the provider
Send the patient’s blood sample and the enrollment form to: DNA Diagnostic Lab, CMSC 10-106, Johns Hopkins Hospital, 600 N. Wolfe Street, Baltimore, MD 21287
The lab will analyze your patient’s blood sample and send test results as soon as they become available
The MAP is a valuable program that provides free genotyping and follow-up testing as needed for people with cystic fibrosis.
What are the eligibility requirements for participating in the MAP?
Patients must have a diagnosis of cystic fibrosis and have not yet had genetic testing to determine their CF mutations or have been tested previously but still have one or more unknown mutations. There are no income or insurance requirements.
What are the benefits of participating in the MAP?
The MAP will help providers and patients make informed decisions about their treatment options.
What expenses does the Cystic Fibrosis Foundation (CFF) cover?
The CFF will cover the cost of the genotyping. However, the patient or CF care center is responsible for the cost of the blood sample, and shipping and postage for mailing the sample to the lab.
Where can my CF patient go to get a blood sample taken?
Patients may get their blood drawn at the designated care center lab, if available. Otherwise, it is at the provider’s and patient’s discretion to utilize a lab that is most convenient.
How long will the CF Foundation offer this program?
The demand and need for the MAP program will be evaluated on an ongoing basis. Currently, there is no deadline for the program.
Can a patient participate in this program multiple times?
No. Patients may only participate once.
How long will it take for the care center to receive an authorization number for each approved patient?
Forms will be approved on a first-come, first-served basis. The accuracy and completion of the enrollment form and program volume will determine the time it takes to receive an authorization number.
What types of testing are offered?
All CF patients enrolled in the MAP will receive genotyping for CFTR mutations. Further testing will be conducted if one or more mutations remain unknown after genotyping.
Will the patient’s name and test results be released to the public?
No, patients’ names and corresponding test results will not be released to the public. Test results will be released to the CF Foundation and the referring doctor or CF care center.
When can providers expect test results for their patients?
In order to allocate funds in the most efficient way, testing occurs in batches. It can take up to 60 days to receive genotyping results, and additional time if further testing is needed.
If you have additional questions, call the Mutation Analysis Program at888-315-4154 and press option 2,
or send us an email at MAP@cff.org
